All Outputs (36)

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2024)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., …Williams, H. C. (2024). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, 190(4), 559-564. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases (2024)
Journal Article

Objective To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s). Methods Adu... Read More about Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline (2024)
Journal Article

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK (2024)
Journal Article

Introduction: High‐dose methotrexate (HDMTX) is administered for the treatment of some malignancies. Serious complications after the administration of HDMTX are rare, but occasionally MTX may precipitate in the renal tubes causing a delayed eliminati... Read More about A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Working Paper

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Richter's transformation: Transforming the clinical landscape (2023)
Journal Article

Richter transformation (RT) represents an aggressive histological transformation from chronic lymphocytic leukaemia, most often to a large B cell lymphoma. It is characterised by chemo-resistance and subsequent short survival. Drug development has st... Read More about Richter's transformation: Transforming the clinical landscape.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis (2023)
Journal Article

Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse (2023)
Journal Article

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma (2023)
Journal Article
Di Ciaccio, P. R., Polizzotto, M. N., Cwynarski, K., Gerrie, A. S., Burton, C., Bower, M., …Hamad, N. (2024). The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood, 143(2), 152-165. https://doi.org/10.1182/blood.2023021348

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavourable prognosis. We conducted a multicenter, international, retrospective cohor... Read More about The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 41(35), 5376-5387. https://doi.org/10.1200/JCO.23.00365

PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy (2023)
Journal Article
Cornell, I., Al Busaidi, A., Wastling, S., Anjari, M., Cwynarski, K., Fox, C. P., …Thust, S. C. (2023). Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy. Journal of Personalized Medicine, 13(7), Article 1182. https://doi.org/10.3390/jpm13071182

Primary Central Nervous System Lymphoma (PCNSL) is a highly malignant brain tumour. We investigated dynamic changes in tumour volume and apparent diffusion coefficient (ADC) measurements for predicting outcome following treatment with MATRix chemothe... Read More about Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.

Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing (2023)
Journal Article
Wijaya, R., Johnson, M., Campbell, N., Stuart, B., Kelly, A., Tipler, N., …PROSECO investigators, P. I. (2023). Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing. Lancet, 402(10396), 99-102. https://doi.org/10.1016/S0140-6736%2823%2901180-7

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia (2023)
Journal Article
Jurczak, W., Elmusharaf, N., Fox, C. P., Townsend, W., Paulovich, A. G., Whiteaker, J. R., …Munir, T. (2023). Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia. Therapeutic Advances in Hematology, 14, https://doi.org/10.1177/20406207231173489

Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical act... Read More about Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine, cyclop... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial..

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study (2023)
Journal Article
Figueroa‐Mora, R., Rampotas, A., Halperin, D., Worth, T., Vidler, J., Melotti, D., …Martinez‐Calle, N. (2023). Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study. British Journal of Haematology, 202(1), 48-53. https://doi.org/10.1111/bjh.18738

This retrospective, observational study evaluated patterns of inpatient versus outpatient tumour lysis syndrome (TLS) monitoring during venetoclax ramp-up in 170 patients with chronic lymphocytic leukaemia. The primary outcome was clinical/biochemica... Read More about Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma (2023)
Journal Article
Van Le, H., Van Naarden Braun, K., Nowakowski, G. S., Sermer, D., Radford, J., Townsend, W., …Hasskarl, J. (2023). Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & Lymphoma, 64(3), 573-585. https://doi.org/10.1080/10428194.2022.2160200

This study used a real-world population as a synthetic comparator for the single-arm TRANSCEND NHL 001 study (TRANSCEND; NCT02631044) to evaluate the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional (noncellular) therapies i... Read More about Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients (2022)
Journal Article
Wilson, M. R., Eyre, T. A., Kirkwood, A. A., Wong Doo, N., Soussain, C., Choquet, S., …McKay, P. (2022). Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 139(16), 2499-2511. https://doi.org/10.1182/blood.2021014506

Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We con... Read More about Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.